Using AAVrh10, which has a strong safety profile as a neuronal-specific gene transfer vector, the soluble anti-EGFR antibody distributes into the local microenvironment reducing EGFR-driven GBM growth [24–26] (clinicaltrials.gov, NCT01161576). Here, EGFR is linked to glioblastoma.